Price, David B. http://orcid.org/0000-0002-9728-9992
Carter, Victoria
Martin, Jessica
Gardener, Elizabeth A.
Skinner, Derek
Yang, Sen
Hoffman, Matthias
Willis, Jenna C.
Cooper, Andrew J.
Funding for this research was provided by:
Mundipharma Research Limited
Article History
First Online: 20 November 2019
Compliance with Ethical Standards
:
: David Price has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. Jessica Martin, Elizabeth A. Gardener, and Sen Yang are former employees of the Observational and Pragmatic Research Institute, which has conducted paid research in respiratory disease on behalf of the following organizations in the past 5 years: Almirall, Anaxys, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia (formerly Aerocrine), Harvey Walsh, Mapi, Morningside Healthcare, Mundipharma, Mylan (formerly Meda), Napp, Novartis, Orion, Plymouth University, Regeneron, Respiratory Effectiveness Group, Roche, Sanofi, Takeda, Teva, University of East Anglia, Zentiva (a Sanofi company). Derek Skinner is a current employee of the Observational and Pragmatic Research Institute. Jenna Willis and Andrew J. Cooper are former employees of Mundipharma Research Ltd. Matthias Hoffman is a former employee of Mundipharma Research GmbH and Co. KG.
: This article is based on previously conducted studies, and does not involve any new studies of human subjects performed by any of the authors.
: The dataset analysed during the current study is available from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) at:ExternalRef removed.
: <sup>®</sup>FLUTIFORM is a registered trade mark of Jagotec AG. SERETIDE and ACCUHALER and EVOHALER are registered trade marks of Glaxo Group Limited. SYMBICORT and TURBOHALER are registered trade marks of AstraZeneca AB. FOSTAIR and NEXTHALER are registered trade marks of Chiesi Farmaceutici S.p.A.